Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...

Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...

Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...

Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

DexCom, Inc. (NASDAQ:DXCM) has also consistently beat EPS estimates in the last 4 quarters. The stock has received an average ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

Continuous Glucose Monitoring Devices Market to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9% between 2024 and 2031 BURLINGAME, CA, UNITED STATES, October 15, 2024 /EINPresswire / -- A ...

The medical device market is set to grow from over $500B to nearly $890B by 2032. Top medical device stocks include Abbott Laboratories and GE Healthcare. Investment options also include medical ...